CymaBay Therapeutics Inc. (CBAY)
| Market Cap | 347.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.65M |
| Shares Out | 68.89M |
| EPS (ttm) | -0.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 2 |
| Last Price | $4.92 |
| Previous Close | $5.11 |
| Change ($) | -0.19 |
| Change (%) | -3.72% |
| Day's Open | 5.14 |
| Day's Range | 4.89 - 5.18 |
| Day's Volume | 964,771 |
| 52-Week Range | 1.21 - 9.06 |
Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.
NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for ...
NEWARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chro...
The FDA lifted all holds on all CymaBay liver disease studies back in July, since, shares have begun clawing back, +319% upside YTD. The company has presented positive top-line data from the E...
CymaBay Therapeutics (CBAY) CEO Sujal Shah on Q3 2020 Results - Earnings Call Transcript
The AdventHealth Translational Research Institute (TRI) in Orlando, FL to lead the study, funded by the Helmsley Charitable Trust, evaluating MBX-2982, a GPR119 agonist, for its ability to inc...
NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chro...
Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.
NEWARK, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies fo...
While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
CymaBay Therapeutics, Inc.'s (CBAY) CEO Sujal Shah on Q2 2020 Results - Earnings Call Transcript
NEWARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other ch...
CymaBay Therapeutics Inc. (NASDAQ: CBAY) posted a huge gain to start the week after the company reported results from a late-stage clinical study for the treatment of primary biliary cholangit...
Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC
Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBC
Investors need to pay close attention to CymaBay (CBAY) stock based on the movements in the options market lately.
The development-stage company might be able to resume the development of its lead drug candidate, which was halted in late 2019.
CymaBay Therapeutics, Inc. Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders CymaBay Therapeutics, Inc. Announces Change to Virtual Format for 2020 Annual Meeting of S...
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
A do-over on one of its drugs is a potential game-changer for CymaBay.
CymaBay Therapeutics (CBAY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.
Non-alcoholic steatohepatitis biotechs are increasingly finding it difficult to make headway, and the lack of any approved therapy despite a slew of research is a testament to the challenge.
CymaBay Therapeutics Inc. (NASDAQ: CBAY) shares more than doubled on Tuesday after the company announced its first-quarter results, along with a corporate update.
Shares of CymaBay Therapeutics Inc. CBAY, +123.91% rocketed on in very active morning trading Tuesday, after an upbeat report on results of a study of its treatment of liver disease prompted a...
CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q1 2020 Results - Earnings Call Transcript
RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.
CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q4 2019 Results - Earnings Call Transcript
Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.
NEWARK, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other ch...
CymaBay Therapeutics, Inc. (CBAY) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
Even in a winning market, these stocks fell. Find out why.
The company has halted the development of its lead drug candidate in one indication and terminated two other studies involving the compound.
CymaBay Therapeutics Inc (NASDAQ: CBAY) shares are losing more than 75% of their value Monday after the company said it's halting the development of its lead drug, seladelpar.
Shares of CymaBay Therapeutics Inc. CBAY, +6.12% are down 11% in premarket trading after the biopharmaceutical company ended two studies and halted a third for its experimental drug seladelpar.
Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q3 2019 Results - Earnings Call Transcript
Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.
NEWARK, Calif., Oct. 14, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovati...
NEWARK, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY) today announced that two abstracts related to its seladelpar development program for the treatment ...
NEWARK, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovat...
NEWARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovat...
Primary Sclerosing Cholangitis is an orphan disease with no FDA approved therapeutic options or viable alternatives except surgical interventions.
Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2019 Results - Earnings Call Transcript
Seladelpar is a specific, new generation PPAR-δ agonist in mid-late phase clinical development for NASH and cholestatic liver diseases, PBC and PSC.
CymaBay Therapeutics tumbled on reporting 12-week data from its phase 2b study using seladelpar to treat patients with nonalcoholic steatohepatitis.
While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.
Disappointing news and downbeat views hurt some stocks.
The company reported disappointing interim data from an ongoing phase 2b trial in NASH, but it wasn't all bad news.
About CBAY
CymaBay Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor ago... [Read more...]
| Industry Biotechnology | |
| CEO Sujal Shah | Employees 36 |
| Stock Exchange NASDAQ | Ticker Symbol CBAY |
Analyst Forecasts
According to 11 analysts, the average rating for CBAY stock is "Strong Buy." The 12-month stock price forecast is 13.09, which is an increase of 166.06% from the latest price.